Literature DB >> 33572677

Changes in the Expression of TBP-2 in Response to Histone Deacetylase Inhibitor Treatment in Human Endometrial Cells.

Hye In Kim1,2, Seok Kyo Seo1,2, Seung Joo Chon3, Ga Hee Kim2, Inha Lee1,2, Bo Hyon Yun1,2.   

Abstract

Histone deacetylase inhibitors (HDACi) induce apoptosis preferentially in cancer cells by caspase pathway activation and reactive oxygen species (ROS) accumulation. Suberoylanilide hydroxamic acid (SAHA), a HDACi, increases apoptosis via altering intracellular oxidative stress through thioredoxin (TRX) and TRX binding protein-2 (TBP-2). Because ROS accumulation, as well as the redox status determined by TBP-2 and TRX, are suggested as possible mechanisms for endometriosis, we queried whether SAHA induces apoptosis of human endometrial cells via the TRX-TBP-2 system in endometriosis. Eutopic endometrium from participants without endometriosis, and ectopic endometrium from patients with endometriosis, was obtained surgically. Human endometrial stromal cells (HESCs) and Ishikawa cells were treated with SAHA and cell proliferation was assessed using the CCK-8 assay. Real-time PCR and Western blotting were used to quantify TRX and TBP-2 mRNA and protein expression. After inducing oxidative stress, SAHA was applied. Short-interfering TRX (SiTRX) transfection was performed to see the changes after TRX inhibition. The mRNA and protein expression of TBP-2 was increased with SAHA concentrations in HESCs significantly. The mRNA TBP-2 expression was decreased after oxidative stress, upregulated by adding 2.5 μM of SAHA. The TRX/TBP-2 ratio decreased, apoptosis increased significantly, and SiTRX transfection decreased with SAHA. In conclusion, SAHA induces apoptosis by modulating the TRX/TBP-2 system, suggesting its potential as a therapeutic agent for endometriosis.

Entities:  

Keywords:  apoptosis; endometriosis; oxidative stress; suberoylanilide hydroxamic acid; thioredoxin

Year:  2021        PMID: 33572677      PMCID: PMC7866992          DOI: 10.3390/ijms22031427

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  33 in total

1.  Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Authors:  Noemi Reguart; Rafael Rosell; Felipe Cardenal; Andres F Cardona; Dolores Isla; Ramon Palmero; Teresa Moran; Christian Rolfo; M Cinta Pallarès; Amelia Insa; Enric Carcereny; Margarita Majem; Javier De Castro; Cristina Queralt; Miguel A Molina; Miquel Taron
Journal:  Lung Cancer       Date:  2014-03-02       Impact factor: 5.705

2.  Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.

Authors:  Thomas Prebet; Jacques Delaunay; Eric Wattel; Thorsten Braun; Pascale Cony-Makhoul; Sophie Dimicoli; Stephan Wickenhauser; Julie Lejeune; Sylvie Chevret; Fatiha Chermat; Pierre Fenaux; Norbert Vey
Journal:  Br J Haematol       Date:  2016-12-15       Impact factor: 6.998

3.  Diagnostic delay for endometriosis in Austria and Germany: causes and possible consequences.

Authors:  G Hudelist; N Fritzer; A Thomas; C Niehues; P Oppelt; D Haas; A Tammaa; H Salzer
Journal:  Hum Reprod       Date:  2012-09-17       Impact factor: 6.918

4.  In vivo redox state of human thioredoxin and redox shift by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

Authors:  J Ungerstedt; Y Du; H Zhang; D Nair; A Holmgren
Journal:  Free Radic Biol Med       Date:  2012-09-23       Impact factor: 7.376

5.  Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.

Authors:  J S Ungerstedt; Y Sowa; W-S Xu; Y Shao; M Dokmanovic; G Perez; L Ngo; A Holmgren; X Jiang; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-06       Impact factor: 11.205

Review 6.  Histone deacetylase inhibitors.

Authors:  Paul A Marks; Victoria M Richon; Thomas Miller; William Kevin Kelly
Journal:  Adv Cancer Res       Date:  2004       Impact factor: 6.242

7.  Distinct developmental trajectories of endometriotic epithelium and stroma: implications for the origins of endometriosis.

Authors:  Vivian Lac; David G Huntsman
Journal:  J Pathol       Date:  2018-10-01       Impact factor: 7.996

8.  Pathophysiology of Endometriosis: Role of High Mobility Group Box-1 and Toll-Like Receptor 4 Developing Inflammation in Endometrium.

Authors:  Bo Hyon Yun; Seung Joo Chon; Young Sik Choi; SiHyun Cho; Byung Seok Lee; Seok Kyo Seo
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

9.  Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.

Authors:  Shinya Oki; Kenbun Sone; Katsutoshi Oda; Ryuji Hamamoto; Masako Ikemura; Daichi Maeda; Makoto Takeuchi; Michihiro Tanikawa; Mayuyo Mori-Uchino; Kazunori Nagasaka; Aki Miyasaka; Tomoko Kashiyama; Yuji Ikeda; Takahide Arimoto; Hiroyuki Kuramoto; Osamu Wada-Hiraike; Kei Kawana; Masashi Fukayama; Yutaka Osuga; Tomoyuki Fujii
Journal:  Oncotarget       Date:  2017-06-20

Review 10.  Theories on the pathogenesis of endometriosis.

Authors:  Samer Sourial; Nicola Tempest; Dharani K Hapangama
Journal:  Int J Reprod Med       Date:  2014-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.